Abstract
|
PLOD3 is Upregulated in Gastric Cancer and Correlated with Clinicopathologic Characteristics
by Biao Wang, Lingyan Xu, Yugang Ge, Xiaomin Cai, Qiang Li, Zhengyi Yu, Jiawei Wang, Ying Wang, Chao Lu, Danping Wang, Yuanyuan Wang,
Xiaofeng Chen, Yanhong Gu
|
|
|
Background: Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3 (PLOD3) has been proven to be involved in various human cancers; however, the function of PLOD3 in gastric cancer (GC) remains unclear. In this study, the role of PLOD3 in GC was evaluated.
Methods: The expression of PLOD3 in GC tissues and normal tissues was predicted by The Cancer Genome Atlas (TCGA). The kmplot online tool was performed to evaluate the impact of PLOD3 expression on GC patients’ survival. Real-time PCR was conducted to verify PLOD3 expression in our own clinical samples and GC cells. The Cell Counting Kit-8 and the colony formation assay were used to detect GC cell proliferation ability.
Results: PLOD3 was upregulated in human GC tissues (compared to adjacent normal tissues, p < 0.001) and GC cells. High expression of PLOD3 was significantly correlated with larger tumor size (p = 0.007) and poor prognosis. Inhibition of PLOD3 could suppress cell proliferation in GC.
Conclusions: These results revealed that PLOD3 may promote the progression of GC.
DOI: 10.7754/Clin.Lab.2018.180541
|
